CSL Limited (CSL), a biotechnology company, specializes in developing and delivering innovative medicines to save lives and improve the quality of life for individuals with serious health conditions. The company focuses primarily on the development a…
Analysis
Middle-of-the-road
CSL Limited sits in the middle of our grid: average quality, average price, no obvious signal in either direction.
On valuation, the picture is fair. The owner-earnings multiple stands at 21.1×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 7% a year, against analyst forecasts of 2%. The gap between price and consensus is worth watching: demanding expectations.
Growth is tepid; the safety picture is adequate. The company scores 12/20 on our value-creation score: creating some value. Analyst sentiment is cautious.
No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.
360° rank · history
1007550250
Feb 202622
59
2026
All-time high
64
Mar 2026
All-time low
22
Feb 2026
Average rank
48
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
53
—
—
—
Price/Earnings
68
—
—
—
Price/Book
61
—
—
—
Dividend Yield
87
—
—
—
Value (overall)
79
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.